SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-083579
Filing Date
2022-12-29
Accepted
2022-12-29 16:30:39
Documents
14
Period of Report
2022-12-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea170960-8k_180lifesci.htm   iXBRL 8-K 33430
2 THIRD AMENDMENT TO CONSULTING AGREEMENT DATED DECEMBER 28, 2022, BETWEEN 180 LIF ea170960ex10-1_180lifesci.htm EX-10.1 18631
  Complete submission text file 0001213900-22-083579.txt   279681

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnf-20221228.xsd EX-101.SCH 3992
4 XBRL DEFINITION FILE atnf-20221228_def.xml EX-101.DEF 26629
5 XBRL LABEL FILE atnf-20221228_lab.xml EX-101.LAB 36680
6 XBRL PRESENTATION FILE atnf-20221228_pre.xml EX-101.PRE 25253
8 EXTRACTED XBRL INSTANCE DOCUMENT ea170960-8k_180lifesci_htm.xml XML 5692
Mailing Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306
Business Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

IRS No.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 221499141
SIC: 2834 Pharmaceutical Preparations